Cannabis Bioscience International Holdings, Inc. (CBIH) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
6201 BONHOMME ROAD HOUSTON, TX 77036 |
| State of Incorp. | |
| Fiscal Year End | May 31 |
| Industry (SIC) | 8731 - Commercial Physical and Biological Research (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 8/31/2025 MRQ | 5/31/2025 | 11/30/2024 MRQ | 5/31/2024 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Receivables | 16 | 14 | 20 | |||
| Other current assets | 1 | 1 | 1 | |||
| Other undisclosed current assets | 13 | 1 | 1 | |||
| Total current assets: | 29 | 15 | 21 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 3 | 19 | 36 | |||
| Total noncurrent assets: | 3 | 19 | 36 | |||
| TOTAL ASSETS: | 32 | 35 | 57 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 100 | 166 | 196 | |||
| Accrued liabilities | 22 | |||||
| Other undisclosed accounts payable and accrued liabilities | 78 | 166 | 196 | |||
| Debt | 126 | 129 | 161 | |||
| Derivative instruments and hedges, liabilities | 29 | |||||
| Other undisclosed current liabilities | 690 | 577 | 525 | |||
| Total current liabilities: | 946 | 873 | 882 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation | 250 | 250 | 249 | |||
| Long-term debt, excluding current maturities | 250 | 250 | 249 | |||
| Liabilities, other than long-term debt | 5 | |||||
| Operating lease, liability | 5 | |||||
| Other undisclosed noncurrent liabilities | 77 | |||||
| Total noncurrent liabilities: | 250 | 327 | 254 | |||
| Total liabilities: | 1,195 | 1,200 | 1,136 | |||
| Equity | ||||||
| Equity, attributable to parent | (1,164) | (1,165) | (1,079) | |||
| Additional paid in capital | 4,719 | 4,325 | 4,255 | |||
| Accumulated deficit | (5,883) | (5,490) | (5,334) | |||
| Total equity: | (1,164) | (1,165) | (1,079) | |||
| TOTAL LIABILITIES AND EQUITY: | 32 | 35 | 57 | |||
Income Statement (P&L) ($ in thousands)
| 8/31/2025 TTM | 5/31/2025 | 11/30/2024 TTM | 5/31/2024 | ||
|---|---|---|---|---|---|
| Revenues | 303 | 365 | 249 | ||
| Cost of revenue | (40) | (38) | (46) | ||
| Gross profit: | 263 | 328 | 203 | ||
| Operating expenses | (684) | (674) | (689) | ||
| Operating loss: | (421) | (347) | (486) | ||
| Nonoperating expense | (127) | (154) | (165) | ||
| Interest and debt expense | 24 | (130) | |||
| Net loss: | (525) | (631) | (651) | ||
| Other undisclosed net income (loss) attributable to parent | (24) | 130 | 0 | ||
| Net loss available to common stockholders, diluted: | (549) | (501) | (651) | ||
Comprehensive Income ($ in thousands)
| 8/31/2025 TTM | 5/31/2025 | 11/30/2024 TTM | 5/31/2024 | ||
|---|---|---|---|---|---|
| Net loss: | (525) | (631) | (651) | ||
| Comprehensive loss, net of tax, attributable to parent: | (525) | (631) | (651) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.